Monogram Technologies (Monogram Technologies) Cash And Cash Equivalents : $10.08 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Monogram Technologies Cash And Cash Equivalents?

Monogram Technologies's quarterly cash and cash equivalents declined from Sep. 2023 ($14.88 Mil) to Dec. 2023 ($13.59 Mil) but then stayed the same from Dec. 2023 ($13.59 Mil) to Mar. 2024 ($10.08 Mil).

Monogram Technologies's annual cash and cash equivalents increased from Dec. 2021 ($5.54 Mil) to Dec. 2022 ($10.47 Mil) and increased from Dec. 2022 ($10.47 Mil) to Dec. 2023 ($13.59 Mil).

Monogram Technologies Cash And Cash Equivalents Historical Data

The historical data trend for Monogram Technologies's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Technologies Cash And Cash Equivalents Chart

Monogram Technologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

2.32

5.59

5.54

10.47

13.59

Monogram Technologies Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial												7.72	17.10	14.88	13.59	10.08

Monogram Technologies Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Monogram Technologies (NAS:MGRM) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Monogram Technologies Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Monogram Technologies's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Monogram Technologies (Monogram Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Technologies Inc (NAS:MGRM) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

J7J:Germany

Address

3913 Todd Lane, Suite 307, Austin, TX, USA, 78744

Website

https://www.monogramorthopedics.com

Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Executives

Paul H Riss	director
Noel Knape	officer: Chief Financial Officer	3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson	director, 10 percent owner, officer: Chief Executive Officer	3913 TODD LANE, AUSTIN TX 78744
Noel Goddard	director	3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei	officer: Chief Technology Officer	3913 TODD LANE, AUSTIN TX 78744
Douglas Unis	director	3913 TODD LANE, AUSTIN TX 78744